Recent News

• 11.10.2025 - Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial
• 11.10.2025 - Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial
• 10.27.2025 - FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial
• 10.01.2025 - Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
• 09.24.2025 - Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
• 09.18.2025 - First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial
• 09.18.2025 - Yun Zhong, Ph.D.
• 09.18.2025 - Jonathan Wolleben
• 09.18.2025 - Edward Nash
• 09.17.2025 - Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Recent Filings

• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.23.2025 - EX-99.1 EX-99.1
• 10.23.2025 - 8-K Current report
• 08.22.2025 - 8-K Current report
• 08.14.2025 - 8-K Current report
• 08.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors